Zhang Zhaofu, Wang Hao, Chen Youpeng
Department of Infectious Diseases, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Front Nutr. 2024 Jul 22;11:1412516. doi: 10.3389/fnut.2024.1412516. eCollection 2024.
The development of metabolic dysfunction associated steatotic liver disease (MASLD) has been associated with lipid accumulation, oxidative stress, endoplasmic reticulum stress, and lipotoxicity. The Composite Dietary Antioxidant Index (CDAI) is a comprehensive score representing an individual intake of various dietary antioxidants, including vitamin A, vitamin C, vitamin E, selenium, zinc, and carotenoids. This study investigated the association between CDAI and MASLD.
Clinical and demographic data, as well as ultrasound transient elastography measurements at baseline, were collected from the National Health and Nutrition Examination Survey 2017-2020 (NHANES 2017-2020). The controlled attenuation parameter was utilized to diagnose the presence of hepatic steatosis and to categorize individuals into those with and without MASLD. Liver stiffness was measured by ultrasound transient elastography, and subjects were classified as those with and without advanced liver fibrosis.
This study included 5,884 adults, of whom 3,433 were diagnosed with MASLD, resulting in a weighted prevalence of 57.3%. After adjusting for covariates, the odds ratios for MASLD were 0.96 (95% CI: 0.82, 1.12) in the second quartile, 0.80 (95% CI: 0.68, 0.95) in the third quartile and 0.60 (95% CI: 0.49, 0.73) in the fourth quartile, respectively. CDAI, however, was not significantly associated with advanced liver fibrosis.
These findings suggested that scores on the CDAI were linearly and negatively associated with the prevalence of MASLD in the United States adults.
代谢功能障碍相关脂肪性肝病(MASLD)的发展与脂质蓄积、氧化应激、内质网应激和脂毒性有关。复合膳食抗氧化指数(CDAI)是一个综合评分,代表个体对各种膳食抗氧化剂的摄入量,包括维生素A、维生素C、维生素E、硒、锌和类胡萝卜素。本研究调查了CDAI与MASLD之间的关联。
从2017 - 2020年美国国家健康与营养检查调查(NHANES 2017 - 2020)中收集临床和人口统计学数据,以及基线时的超声瞬时弹性成像测量值。利用受控衰减参数诊断肝脂肪变性的存在,并将个体分为患有和未患有MASLD的两组。通过超声瞬时弹性成像测量肝脏硬度,并将受试者分为有和没有进展性肝纤维化的两组。
本研究纳入了5884名成年人,其中3433人被诊断为MASLD,加权患病率为57.3%。在调整协变量后,第二四分位数中MASLD的优势比为0.96(95%置信区间:0.82, 1.12),第三四分位数中为0.80(95%置信区间:0.68, 0.95),第四四分位数中为0.60(95%置信区间:0.49, 0.73)。然而,CDAI与进展性肝纤维化无显著关联。
这些发现表明,在美国成年人中,CDAI评分与MASLD的患病率呈线性负相关。